40 results about "Anesthesia analgesia" patented technology

Pharmaceutical compositions comprising a narcotic analgesic in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and other micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal mucosa of the mouth.

A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg / ml-160 mg / ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and / or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v / v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v / v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.

A ropivacaine methanesulfonate as anesthetic or analgetic has a chemical formula: (-)-(S)-N-(2,6-dimethylphenyl)-1-propyl piperidine-2-formamide methanesulfonate, and is prepared through preparing raw materials, dissolving, adding, methane sulfonic acid, adding ketone solvent, filtering, baking and recrystallizing. Its advantages are high stability and output rate and low cost.

The invention belongs to the technical field of herbal anaesthesia of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition with an auxiliary anesthetic effect. The traditional Chinese medicine composition is prepared from the following Chinese medicinal raw materials: 1-3 parts of datura stramonium, 1-3 parts of henbane, 5-10 parts of passion flowers, 3-5 parts of daphne giraldii, 5-8 parts of fourstamen stephania roots, 3-5 parts of radix scutellariae, 3-5 parts of Chinese herbaceous peony, 1-3 parts of olibanum, 1-3 parts of myrrh, 1-3 parts of caulis spatholobi, 1-3 parts of hematoxylon, 1-3 parts of ligusticum wallichii, 3-5 parts of dragon bone, 1-3 parts of nacre, 3-5 parts of oyster, 1-3 parts of platycladi seeds, 1-3 parts of tuber fleeceflower stem and 1-3 parts of liquorice. A decoction is prepared. Due to the efficacies of the traditional Chinese medicines for narcotizing, easing pain, relieving spasm and checking convulsions, combination of the medicinal materials with the effects of relaxing tendons, activating collaterals, and relaxing skeletal muscle, and optimization of the medicine proportion, psychentonia is reduced, and the effect of auxiliary anesthesia analgesia before an operation is achieved.

The invention discloses a multi-channel intelligent drug delivery system, which comprises: a data acquisition and transmission terminal, a TCI target control system, a wireless communication terminal,a calculation and data management terminal; The data acquisition and transmission terminal collects a scalp electrode to record an EEG signal; through the decomposition and reconstruction of the brain wave signal, the cortex and subcortical EEG can be extracted, and a two-compartment model of the cortex and subcortex is established for interactive analysis; for the pre-processed brain wave data,a waveform recognition algorithm and a wavelet analysis algorithm are applied to obtain different brain state objective theorem measurement data; A computer controlled drug-delivery technique is characterized by maintaining the drug concentration in the blood by a TCI target control system. The system can realize the analgesia and sedation monitoring during the operation, and summarizes the physiological indicator data of other monitors through a wireless data transmission technology, the concentration of an effect chamber in anesthesia is adjusted within a reasonable range, and the technicalproblem of ideal individual-specific multi-channel anesthesia analgesia and sedation is realized by the TCI technology.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a local anesthetic for an operative incision. The local anesthetic is prepared from the following traditional Chinese medicine materials in parts by weight: 5-10 parts of girald daphne bark, 5-15 parts of flos daturae, 5-10 parts of passion flower, 5-10 parts of hyoscyamus niger, 3-5 parts of decumbent corydalis tuber, 3-8 parts of shinyleaf pricklyash root, 3-5 parts of cynanchum paniculatum, 3-5 parts of centipede, 1-3 parts of caulis spatholobi, 1-3 parts of unprocessed semen strychni, 3-5 parts of asarum, 3-5 parts of arenobufagin, 3-5 parts of pepper, 3-5 parts of angelica sinensis, 3-5 parts of arisaema erubescens and 1-3 parts of flos carthami. The local anesthetic is prepared into a surgical dressing by virtue of a preparation method and used in a local anaesthesia fiber so as to be bound at an operative incision. Through the efficacies of anesthesia, analgesia, spasmolysis and convulsion check and the efficacies of drawing out poison, promoting granulation, removing blood stasis and relieving pain, the effects of rapid permeation, sedation and analgesia before an operation are achieved; the dosage of the injected local anesthetic is reduced in an assisting manner; and the local anesthetic has multiple effects of lasting anesthesia and analgesia after the operation, promoting incision healing and the like.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

The invention discloses a painless microneedle and a preparation method thereof. The painless microneedle comprises a needle body and a functional layer, wherein the needle body comprises a needle handle and a needle tip; the needle handle is connected with the functional layer; the functional layer comprises a self-heating layer and a magnetic therapy layer or a traditional Chinese medicine layerarranged below the self-heating layer. The painless microneedle disclosed by the invention has the effects of slight anesthesia and analgesia, and does not cause pain after being used for a long time; the self-heating layer is provided with an isolation film which can be uncovered, and after the isolation film is uncovered, the self-heating layer makes contact with air to start heating; the magnetic therapy layer or the traditional Chinese medicine layer can dredge channels and collaterals, regulate qi and blood, resist inflammation and ease pain, and directly acts on an affected part by means of heating of the heating layer, and medicine efficacy permeation is better.

The invention provides a preparation method for a compound with a long-acting treatment effect. The compound can be used for preparing medicines having anti-depression, anesthetic or analgesic effectsor capable of improving cognitive functions, protecting the lungs, treating amyotrophic lateral sclerosis or treating complex regional pain syndrome.

The invention belongs to the technical field of medical apparatuses and instruments and provides a nerve-blocking puncture catheter needle with an adjustable puncture head. The catheter needle mainly consists of a puncture catheter and a puncture needle core. During operation, the puncture needle core is sleeved by the puncture catheter, and the sharp end of the puncture needle core extends out of a port of the puncture catheter and has sharpness. Under the ultrasonic guidance, the sharp end of the puncture needle core can return to the puncture catheter through adjustment and control when the catheter is close to the target nerve, and the catheter needle loses the sharpness but still has toughness and can continue to penetrate the fascia tissue to be close to the nerve till the catheter needle touches the nerve. Due to the fact that a needle point returns back to the catheter and loses the sharpness, the nerve is not hurt, the catheter needle reaches a target position, the puncture needle core can be directly removed, and the puncture catheter is indwelt around the nerve for future anesthesia medicine application or anesthesia analgesia treatment and other applications.

The invention provides a patch for skin anesthesia, wherein the patch for skin anesthesia comprises the components in parts by weight: 2 to 15 parts of a film forming material, 0.5 to 1 part of a thickening agent, 5 to 10 parts of anesthetic, 17 to 68 parts of a transdermal absorbent, 0.1 to 0.8 part of a bacteriostatic agent and 36 to 67 parts of water. The patch for skin anesthesia is stable indosage, easy to operate, short in onset time, long in drug efficacy time and high in anesthesia analgesia depth.

The invention belongs to the field of pharmacy, and mainly relates to a non-addiction local anesthesia analgesic sustained-release drug delivery system and a method for preparing the same. The sustained-release drug delivery system comprises analgesics, solvents and sustained-release preparations. The analgesics are compositions of bupivacaine free alkali or bupivacaine salts and morphine; the solvents are one or two of ethyl alcohol, benzyl alcohol, benzyl benzoate, ethyl lactate and tetrahydrofuran polyglycol ether; the sustained-release preparations are one or two of soybean oil, ethyl oleate and castor oil. The non-addiction local anesthesia analgesic sustained-release drug delivery system and the method have the advantages that the non-addiction local anesthesia analgesic sustained-release drug delivery system is free of addiction, long in analgesic duration time and low in toxicity, obvious analgesic effects can be realized, and only few side effects can be realized; the non-addiction local anesthesia analgesic sustained-release drug delivery system is free of human tissue irritation and influence on healing of postoperative wound, and obvious local anesthesia analgesic treatment effects can be realized for the postoperative wound.

A system for inducing a Pavlovian association of a scent with a state of less-than-moderate pain, to thereby minimize perceived pain, and to reduce the need for narcotic analgesics. The system includes at least a physiological sensor configured to detect at least one physiological parameter of the user. The physiological parameter of the user may include heart rate variability, blood pressure, galvanic skin response, movement, facial expression and the like. After detection of the physiological parameter, an activation signal is then transmitted to an automatically activated scent diffuser, which diffuses a scent, as a function of the electronic activation signal. The scent may include one or more scent liquids, such as perfumes, essential oils, or the like. Activation of the scent diffuser is maintained by a control circuit that receives the detection signal from the at least one physiological sensor, ascertains that the user has transitioned to a state of less-than-moderate pain, and transmits a signal to the automatically activated scent diffuser. After an association, wherein association further includes conditioning, is created in the user, by iterative performance of the foregoing steps, the user can manually activate a second scent source, in order to trigger a conditioned reflex to assist the user in reducing pain levels.

The invention relates to a pharmaceutical composition which comprises liquid oil and at least one pharmaceutically acceptable gelator. The composition is semi-solid at normal temperature, can be directly used as a medicine storage cavern at the administration part, is convenient for clinical administration, is small in irritation, and has good medication safety and tolerance. The composition is especially suitable for development of pharmaceutical preparations with anesthesia and analgesic activity, has more advantages compared with other slow-release analgesic systems, is continuous and stable in release of analgesic active ingredients, can be used for injection administration, is suitable for stable and convenient local administration, and is good in patient tolerance and few in side effects.

The invention discloses a pharmaceutical composition having abirritation and sedation, which comprises alfentanil and fospropofol disodium, wherein the weight ratio of alfentanil and fospropofol disodium is 1: (100 to 2500). The pharmaceutical composition is used in a form of a conventional medicine preparation, and a preferential medicament form is injection. By combining narcotic analgesic and narcotic sedative, better abirritation and better sedation can be realized, and times for applying medicine can be reduced, so that the anesthesia induction process is more convenient.

A multimodal anti-emetic anesthetic / analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free / sparing anesthetic / analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics / analgesics. The formulation is administered to a mammal in need of anesthesia / analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.

The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises liquid oil, a pharmaceutically acceptable gelator, a pharmaceutically acceptable stabilizer and a pharmaceutically active ingredient. The pharmaceutical composition is especially suitable for development of pharmaceutical preparations with anesthesia and analgesic activity, and has more advantages compared with other sustained-release analgesic systems, for example, release of analgesic active ingredients is continuous and stable, injection administration can be achieved, the pharmaceutical composition is suitable for stable and convenient local administration, patient tolerance is good, and side effects are few.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various types of pain and / or for inhibiting the development of tolerance, and / or physical dependence on a narcotic analgesic substance.

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material; and (c) compressing the blend into a tablet.

The invention relates to the field of medicines, relates to application of a low-addiction HNK derivative in preparation of medicines, and in particular relates to application of the low-addiction HNKderivative in preparation of medicines for treating or preventing depression, including diseases such as complex regional pain syndrome (CRPS) and the like. The compound disclosed by the invention has a structure as shown in a formula I, and can be used for preparing medicines for preventing or treating depression, anesthesia, analgesia, cognitive function improvement, lung protection, amyotrophic lateral sclerosis or complex regional pain syndrome. Compared with the existing known HNK compounds, the compound provided by the invention has longer drug effect time, and the compound provided bythe invention basically does not generate addiction.

A system for inducing a Pavlovian association of a scent with a state of less-than-moderate pain, to thereby minimize perceived pain, and to reduce the need for narcotic analgesics. The system includes at least a physiological sensor configured to detect at least one physiological parameter of the user. The physiological parameter of the user may include heart rate variability, blood pressure, galvanic skin response, movement, facial expression and the like. After detection of the physiological parameter, an activation signal is then transmitted to an automatically activated scent diffuser, which diffuses a scent, as a function of the electronic activation signal. The scent may include one or more scent liquids, such as perfumes, essential oils, or the like. Activation of the scent diffuser is maintained by a control circuit that receives the detection signal from the at least one physiological sensor, ascertains that the user has transitioned to a state of less-than-moderate pain, and transmits a signal to the automatically activated scent diffuser. After an association, wherein association further includes conditioning, is created in the user, by iterative performance of the foregoing steps, the user can manually activate a second scent source, in order to trigger a conditioned reflex to assist the user in reducing pain levels.

The invention discloses a jellyfish toxin polypeptide, belongs to the field of biological chemistry and molecular biology and particularly relates to a jellyfish toxin polypeptide, preparation and application. The amino acid sequence is a bran-new sequence. The polypeptide is synthesized chemically; or a gene recombination method is adopted for expressing polynucleotide capable of coding the polypeptide, and the polypeptide is obtained. The jellyfish toxin polypeptide is used for anesthesia and pain easing in operations. The jellyfish toxin polypeptide, preparation and application have the advantages that the jellyfish toxin polypeptide is used for general anesthesia and pain easing in operations, does not act on an opiate receptor and is free of addiction.

The present disclosure provides a sustained release pharmaceutical composition comprising ketamine pamoate and a pharmaceutically acceptable carrier thereof. The compositions include aqueous suspensions, solutions, and matrix delivery systems that can provide sustained release for anesthesia, analgesia, or treatment of central nervous system and anti-inflammatory diseases.

The invention discloses the application of a combination of polyethylene glycol and local anesthetic in non-narcotic analgesia. In the present invention, the local anesthetic is made into a prodrug or a sustained-release preparation, wherein the high molecular polymer in the prodrug such as polyethylene glycol is covalently bonded with the local anesthetic, and the auxiliary material in the sustained-release preparation plays a sustained-release role Combined with local anesthetics in a non-covalent bond, after administration, there is no anesthesia and analgesic effect before the free local anesthetic is released, and the analgesic effect is released after the free local anesthetic is released, and the local anesthetic of the present invention The prodrug or sustained-release preparation of the drug releases the drug slowly, which can keep the drug concentration stable and lasting within the effective concentration range of non-narcotic analgesia, while significantly reducing the clinical adverse reactions of local anesthetics and reducing the number of administrations. , can achieve long-acting non-narcotic analgesic effect, enhance the effectiveness of the drug, and expand the clinical application range of local anesthetics.

The invention relates to application of a long-acting low-addiction compound in preparation of medicine, in particular to application of the compound in medicine for treating or preventing depression,anesthesia and analgesia and improving cognitive function, lung protection, amyotrophic lateral sclerosis or complex regional pain syndrome. The compound is of a structure as shown in a formula I, and can treat depression, particularly bipolar depression and major depressive disorder. Compared with existing known HNK compounds, the compound has longer drug effect time, and basically does not generate addiction.